Immunotherapy before surgery significantly improves outcomes of patients with melanoma
Source: UCLA, March 2023
If cancer exhibits a weakness, exploit it before taking the target away.
That’s what researchers did in a Phase 2, randomized clinical trial showing that adding immunotherapy before surgical removal of stage III-IV melanoma significantly improved event-free survival and produced no more side effects than standard-of-care treatment, which provides immunotherapy only after surgery.
Results of the multicenter trial, led by a team that included UCLA Jonsson Comprehensive Cancer Center researchers, are published in the March 2, 2023 issue of the New England Journal of Medicine.